Literature DB >> 17171424

Free/total PSA ratio can help in the prediction of high gleason score prostate cancer in men with total serum prostate specific antigen (PSA) of 3-10 ng/ml.

Ahmed A Elabbady1, Mahrousa M Khedr.   

Abstract

PURPOSE: We evaluate the use of free/total prostate specific antigen (PSA) ratio in improving the prediction of cancers of higher Gleason scores. PATIENTS AND METHODS: A total of 164 patients with total serum PSA of 3.0-10.0 ng/ml underwent extended TRUS-guided core biopsy. In each man serum free PSA was measured and the free/total (F/T) PSA ratio was calculated. Out of the 164 patients who underwent TRUS-biopsy, cancer was detected in 62 (37.8%) patients. The mean age for the 62 patients with histologically proven prostate cancer was 62.3+/-5.5 years (49-73). The histological findings were compared with the free/total PSA ratio. Pearson Correlation Coefficient test and Chi-Square test (chi2-test) were used for statistical analysis and p<0.05 was considered statistically significant.
RESULTS: Of the 62 patients, 37 (59.7%) patients had cancers of low Gleason scores (score 2-6) and 25 (40.3%) patients had cancers of high Gleason scores (score 7-10). Free PSA<0.15% was found in 19 (30.6%) patients, from 15 to 20% in 23 (37.1%) patients and >20% in 20 (32.3%) patients. There was a significant positive correlation between total PSA and Gleason score (Pearson Correlation Coefficient test, r=0.328, p<0.01). Also, there was a significant increase in Gleason score with lower F/T PSA ratio (r=-0.668, p<0.001). Among the 19 patients with free PSA ratio<15%, 14 (73.7%) patients had cancers of high Gleason score while 5 (26.3%) patients had cancers of low Gleason score. In patients (n=23) with free PSA ratio15-20%, 10 (43.5%) had cancers of high Gleason score and 13 (56.5%) had cancers of low Gleason score. In the 20 patients with free PSA ratio>20%, 1 patient (5%), had prostate cancer of high Gleason score and the remaining 19 (95%) patients had low Gleason scores. There was a significant relation between lower F/T PSA ratios and higher Gleason scores, Chi-Square test, chi2=19.3, p<0.01.
CONCLUSIONS: In this study, men with prostate cancer and lower F/T PSA ratio were at a higher risk of having higher Gleason scores (7-10) and those with higher F/T PSA ratio were more likely to have lower Gleason scores.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17171424     DOI: 10.1007/s11255-006-6672-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN: 0301-1623            Impact factor:   2.370


  15 in total

Review 1.  PSA updated: still relevant in the new millennium?

Authors:  Jay B Shah; Adam C Reese; James M McKiernan; Mitchell C Benson
Journal:  Eur Urol       Date:  2005-01-12       Impact factor: 20.096

2.  Cancer statistics, 1999.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1999 Jan-Feb       Impact factor: 508.702

3.  Increased accuracy of biopsy Gleason score obtained by extended needle biopsy.

Authors:  P Emiliozzi; S Maymone; A Paterno; P Scarpone; M Amini; G Proietti; M Cordahi; V Pansadoro
Journal:  J Urol       Date:  2004-12       Impact factor: 7.450

4.  Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: influence of total PSA, prostate volume, and age.

Authors:  A W Partin; W J Catalona; P C Southwick; E N Subong; G H Gasior; D W Chan
Journal:  Urology       Date:  1996-12       Impact factor: 2.649

Review 5.  The use of percent free prostate specific antigen for staging clinically localized prostate cancer.

Authors:  J Pannek; H G Rittenhouse; D W Chan; J I Epstein; P C Walsh; A W Partin
Journal:  J Urol       Date:  1998-04       Impact factor: 7.450

6.  Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.

Authors:  Markus Graefen; Pierre I Karakiewicz; Ilias Cagiannos; Peter G Hammerer; Alexander Haese; Jüri Palisaar; Edith Huland; Peter T Scardino; Michael W Kattan; Hartwig Huland
Journal:  J Urol       Date:  2002-03       Impact factor: 7.450

7.  Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy.

Authors:  Bertrand Tombal; Michael Querton; Philippe de Nayer; Philippe Sauvage; Jean Pierre Cosyns; Axel Feyaerts; Renier Opsomer; François X Wese; Paul J Van Cangh
Journal:  Urology       Date:  2002-02       Impact factor: 2.649

8.  Characterizing prostatic adenocarcinomas in men with a serum prostate specific antigen level of < 4.0 ng/mL.

Authors:  M H Sokoloff; X J Yang; M Fumo; D Mhoon; C B Brendler
Journal:  BJU Int       Date:  2004-03       Impact factor: 5.588

9.  Inadequacy of free prostate-specific antigen parameters in the prediction of pathologic extent of prostate cancer in Japanese men.

Authors:  S Egawa; K Suyama; S Soh; S Kuwao; T Uchida; K Koshiba
Journal:  Urology       Date:  1998-08       Impact factor: 2.649

10.  Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer.

Authors:  U H Stenman; M Hakama; P Knekt; A Aromaa; L Teppo; J Leinonen
Journal:  Lancet       Date:  1994-12-10       Impact factor: 79.321

View more
  1 in total

1.  Predictive role of free prostate-specific antigen in a prospective active surveillance program (PRIAS).

Authors:  Hanna Vasarainen; Jolanda Salman; Heidi Salminen; Riccardo Valdagni; Tom Pickles; Chris Bangma; Monique J Roobol; Antti Rannikko
Journal:  World J Urol       Date:  2015-03-31       Impact factor: 4.226

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.